Scemblix (asciminib) - Novartis
A novel BCR::ABL1 I502T mutation associated with acquired asciminib resistance in CML. (PubMed, Leuk Res) - Oct 7, 2026 - No abstract available 
Journal • ABL1
http://www.ncbi.nlm.nih.gov/pubmed/42837802
 
Eunice S Wang; Evan Lee; Laurie Horsch; Leslie N Martinez-Gutierrez; Murugan Selvam; Pamela J Sung; Rahul Kumar Thakur; Tishira Shah
 
Oct 7, 2026
 
Prev Next